Cancer is one of the most common causes of death in the world [1]. Early diagnosis is necessary to save the patient's life, therefore it is important to focus on developing new sensitive diagnostic methods. Glycans perform many important functions in the body. In many types of cancer (prostate, stomach, colon, lungs ...) aberrant glycans are produced in the cell, to which the immune system responds by producing autoantibodies. Such antibodies may be present in the blood before the clinical signs of the disease and they are potential biomarkers of cancer at an early stage [2]. In this work, we focused on the preparation of various glycan surfaces used for the detection of autoantibodies to aberrant glycan structures.
We focused on optimizing the conditions in the preparation of a glycan biosensor sensitive to anti-Tn antibody and lectin Dolichos Biflorus Agglutinin (DBA). The main electrochemical method for determining glycan-protein interactions was differential pulse voltammetry (DPV). The developed biosensor detected an analyte with high selectivity and sensitivity at the atomolar level (1 aM) [3].
In this work, we focused on the development of a new test based on magnetic particles (SUMBA) for the detection of antibodies against aberrant glycans. The SUMBA method has been optimized to be able to recognize aberrant glycans attached to a BSA protein backbone that functions as a molecular nanocarrier of small glycan structures. The entire SUMBA was optimized using analytical techniques such as surface plasmon resonance. Using the SUMBA method, we were able to detect antiglycan antibodies ultrasensitive with a detection limit at the picomolar level (0,45 pM) [4].
Congratulation to your
Congratulation to your results, very nice study. I just want to ask, where did you get that human serum sample of healthy individuals (not mentioned). Is here any cooperation with medical facilities? How many samples did you analysed in total for your study, in meanning of reproducibility of the acquired data. Thank you in advance for you reply, Keep doing great job! Best regards, ZB
Thank you very much for the
Thank you very much for the question and opening the discussion.
Yes, we have a partnership with an oncology doctor who provides us with serum samples from cancer patients. However, healthy serum is commercially available from Merck and is subjected to analysis and supplied with basic data, which guarantees the reproducibility of the measurement. In this work, purchased sera are used to maintain reproducibility during optimization of the method. Each measurement was performed at least twice in triplets.
If you have any further questions, please do not hesitate to contact me.
Thank you and have a nice day.
Anna
Thank you for your reply,
Thank you for your reply, wish you all the best within your further research activities. Cordially, ZB